Am J Physiol Endocrinol Metab 2022
Biallelic mutations in FDXR cause neurodegeneration associated with inflammation
Clinical pipeline note (December 2025): Novo Nordisk filed a New Drug Application (NDA) with the FDA on December 18, 2025 for CagriSema a fixed-dose weekly combination of cagrilintide + semaglutide for weight management
The most common side effect of Ramelteon is drowsiness or tiredness
Presented under catalog identifier Glow-Blend, this three-peptide complex combines BPC-157, TB-500 (thymosin beta-4 fragment), and GHK-Cu (glycyl-L-histidyl-L-lysine copper tripeptide) in a single lyophilized preparation intended for comparative peptide chemistry, chromatographic method development, and reference-standard workflows
Cng vi GABA, theanine mt ln na c chng minh l ci thin thi gian ng, ngha l mt t thi gian hn chm vo gic ng